CD274 and non-small cell lung carcinoma: The phase I clinical trial (NCT05142189), known as LuCa-MERIT-1, currently recruiting, is testing the mRNA vaccine BNT116 in patients with advanced NSCLC who have a PD-L1 expression of ≥50% after receiving anti-PD-L1 therapy.